Literature DB >> 13816252

Clinical usefulness of riboflavin-tagged isoniazid for self-medication in tuberculous patients.

K W DEUSCHLE, C JORDAHL, G L HOBBY.   

Abstract

Entities:  

Keywords:  ISONIAZID/therapy; TUBERCULOUS PATIENTS; VITAMIN B 2

Mesh：

Substances：

Year:  1960        PMID： 13816252     DOI： 10.1164/arrd.1960.82.1.1

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN： 0003-0805


× No keyword cloud information.
  8 in total

1.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  How useful is riboflavin as a tracer of medication compliance?

Authors:  I E Babiker; P R Cooke; M G Gillett
Journal:  J Behav Med       Date:  1989-02

3.  Compliance with medication among outpatients with uncontrolled hypertension in the Seychelles.

Authors:  P Hungerbuhler; P Bovet; C Shamlaye; B Burnand; B Waeber
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

4.  An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs.

Authors:  G A Ellard; P J Jenner; P A Downs
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

5.  Nontraditional problems of antihypertensive management.

Authors:  P Rudd; K I Marton
Journal:  West J Med       Date:  1979-09

6.  Riboflavin as a tracer of medication compliance.

Authors:  P M Dubbert; A King; S R Rapp; D Brief; J E Martin; M Lake
Journal:  J Behav Med       Date:  1985-09

7.  Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement.

Authors:  Abigail J Herron; John J Mariani; Martina Pavlicova; Christina M Parrinello; Krysten W Bold; Frances R Levin; Edward V Nunes; Maria A Sullivan; Wilfred N Raby; Adam Bisaga
Journal:  Drug Alcohol Depend       Date:  2012-08-22       Impact factor: 4.492

Review 8.  Medication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications Development.

Authors:  David J McCann; Nancy M Petry; Anders Bresell; Eva Isacsson; Ellis Wilson; Robert C Alexander
Journal:  J Clin Psychopharmacol       Date:  2015-10       Impact factor: 3.153
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.